1.) Take any serious offer of acquisition from a viable partner.
2.) If none, relieve Vijay of command, installing either Morrow, Lyons or an up and comer from Amgen that they recruit.
3.) Treat Vijay as the ex president from a different party, in other words, company unbound from the Vijay agenda.
4.) Announce the Vijay administration locked into the wrong product attribute for the A-7 product. Declare the safety advantage and the life style advantage it unlocks sufficient for FDA approval and commercial success. Stress high confidence that Vaxfectin will boost efficacy without impact on the best in category safety and quality of life.
5.) Make speed to market a new company imperative. If that costs money on deals but moves the product faster we take the deal.
6.) Commit to an ethic of transparency. Vical's deal terms and test results need to be widely shared and understood. The benefit of the doubt no longer exists for Vical. The shareholder lawsuits will have merit and cost money if it becomes apparent that Vijay had a moving event rate for the A-7 trial.